France· FR:66063738
VEOZA 45 mg, comprimé pelliculé
A fezolinetant product containing fézolinétant, registered in France by ASTELLAS PHARMA EUROPE (PAYS-BAS). The same ATC class is registered in 14 of our 19 countries.
Checked against Base de données publique des médicaments — BDPM (France) on
Informational only — not a medical device.
Where it is registered
Fezolinetant is registered in 14 of 19 countries.
Countries holding a registration under ATC G02CX06 (fezolinetant), each read from that country’s own register.
- This record: France, from Base de données publique des médicaments — BDPM (France)
- 9 of them publish a price we can compare per daily dose
Fezolinetant · ATC G02CX06
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
Base de données publique des médicaments — BDPM (France)- Active substance
- FÉZOLINÉTANT
- Manufacturer
- ASTELLAS PHARMA EUROPE (PAYS-BAS)
- Country
- France (FR)
- ATC code
- G02CX06
- ATC class
- Fezolinetant
- Defined daily dose
- 45 mg, O
- Reimbursed
- No
- Source register
- Base de données publique des médicaments — BDPM (France)
- Last checked
- September 12, 2026
Packs & prices · 1
- cip13340093028331830 plaquette(s) polyamide aluminium PVC-Aluminium de 1 comprimé (dose unitaire)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Fezolinetant in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaVEOZAAstellas Pharma Europe B.V., Leiden
- United StatesVEOZAHAstellas Pharma US, Inc.
- SwitzerlandVeoza 45 mg, FilmtablettenAstellas Pharma AG
- IrelandVeoza 45 mg film-coated tabletsAstellas Pharma Europe B.V.
- BelgiumVeoza 45 mgAstellas Pharma Europe
- NetherlandsVeoza 45 mg filmomhulde tablettenAstellas Pharma Europe B.V.
- NorwayVeozaAstellas Pharma Europe BV
- PolandVeozaAstellas Pharma Europe B.V.
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Veoza
- Liechtenstein · Veoza
- Norway · Veoza
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Base de données publique des médicaments — BDPM (France). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/a4b36438-5153-450a-9296-84bc8afeece0 GET /v1/drugs/a4b36438-5153-450a-9296-84bc8afeece0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cis": "66063738",
"date_amm": "2023-12-07",
"type_amm": "Procédure centralisée",
"numero_ue": "EU/1/23/1771",
"substance": "FÉZOLINÉTANT",
"atc_source": "fr_atc_restore_2026-09-06",
"statut_amm": "Autorisation active",
"statut_bdm": null,
"forme_pharmaceutique": "comprimé pelliculé",
"voies_administration": "orale",
"etat_commercialisation": "Commercialisée",
"surveillance_renforcee": "Oui"
}See everything about fezolinetant.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.